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Objectives: To eval,uate the util,ity of BGL monitor- 
ing in neutropenic cancer pts at high risk of IA and 
IC. 
Methods: Prospective study of consecutive episodes 
of neutropenia (median duration 22 d) in pts with 
acute l,eukemia. IA and IC were defined accord- 
ing to EORTC-MSG criteria. Bl,ood was col,l,ected 
2 times weekl,y before onset of fever and dail,y 
thereafter. BGL was measured by turbidimetric 
or col,orimetric assays (Wako, Japan). Positive 
tests defined by 2 consecutive BGL val,ues >6 and 
>5 pg/ml,, or >11 pg/ml, for both tests (2 cut-off 
val,ues). 
Results: 23 episodes of invasive mycoses oc- 
curred during 130 neutropenic episodes: 12 IC 
(1 proven, 11 probabl,e) and 11 IA (3 proven, 
8 probabl,e). 16 sampl,es/episode (3-35) were an- 
al,yzed over 35 days (17-122). Diagnostic per- 
formance of BGL (turbidimetric test): sensitivity, 
specificity, PPV, NPV, negative l,ikel,ihood ratio were 
43/100/100/86/0.57% and 24/100/100/82/0.76% 
for 2 consecutive val,ues >6 and >11, respec- 
tivel,y. Diagnostic performance of BGL (col,orimet- 
ric test): sensitivity, specificity, PPV, NPV, nega- 
tive l,ikel,ihood ratio were 86/91/72/96/0.15% and 
43/100/100/86/0.57% for 2 consecutive val,ues 
>5 and >11, respectivel,y. Col,orimetric BGL with 
cut-off of 2 consecutives val,ues >5 provided the 
best performance for diagnosis of IA and IC. Me- 
dian time (0d) between fever onset (as first sign 
of IFI) and BGL positivity was significantl,y shorter 
than that between fever onset and conventional. 
diagnosis of IFI (13d) (p < 0.0001). 
Conclusions: Serial. screening of bl,ood beta-l,3-D- 
gl,ucan is a promising non-invasive tool,, in combi- 
nation with other diagnostic methods, to identify 
persistentl,y febril,e neutropenic pts in whom em- 
pirical, therapy may be unnecessary. 
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Objectives: To define the magnitude of the prob- 
l,em, study factors associated with increased risk of 
invasive fungal, infections (IFI) and outcome. 
Methods: From June 1998 to March 2003, al,l, ra- 
diol,ogical, studies of patients with hematol,ogic/ 
oncol,ogic disorders were eval,uated for incl,usion. 
AI,I, cases of invasive fungal, infection were re- 
viewed. The criteria for incl,usion were obvious 
l,esion suggestive of fungal, infection shown on radi- 
ol,ogical, studies, and fungal, infections were cl,assi- 
fled as "proven", "probabl,e', "possibl,e" or "insuf- 
ficient evidence" according to a prior definitions. 
Results: A total, of 1615 patient charts were re- 
viewed. The underl,ying diagnoses incl,ude ALL 410, 
SCT 293, AML 133, non-mal,ignant hematol,- 
ogy 288, NHL/sol,id tumors 491. 152 (9%) had ev- 
idence of fungal, infection (55 [36%] 'definite = 
proven/probabl,e', 97 [64%] 'possibl,e'). Biopsy was 
performed in 94 cases and the findings incl,uded 
budding yeast in 10 patients, septated hyphae 
in 19, and hyphae with no specifications in 12 pa- 
tients. Del,ays in performing diagnostic procedures 
possibl,y resul,ted in the l.ower incidence of 'def- 
inite' IFI (36% vs 64% 'possibl,e"). The overal,l, in- 
cidence of fungal, infection was 9%, being high- 
est for AML (39%), fol,l,owed by ALL (17%). The 
majority of IFI devel,oped during or immediatel,y 
after induction (42% of IFI in AML and 53% of IFI 
in ALL), which can be a target for intervention. 
The infections incl,uded disseminated fungal, infec- 
tion (36%), CDC (11%), pul,monary fungal, infec- 
tion (43%) and asper~illosis (9.5%) incl,uding pul.- 
monary, Para nasal, sinuses, skin and disseminated. 
IFI was radiol,ogical,l,y diagnosed during neutropenia 
in 123 patients (81%). Ten patients died due to 
fungal, infection (7%), 75 (49%) were cured, 26 (17%) 
were al,ive with fungal, infection, and 39 patients 
(26%) died due to primary disease seemingl,y un- 
rel,ated to fungal, infection. Mortal,ity due to IFI 
in this study is l,ess than what is reported in the 
l,iterature and coul,d be a resul,t of our practice 
of earl,y intervention. The average LOS for IFI was 
56 days compared with the usual. 12 days, which 
can add to the increased cost. 
Conclusions: Invasive fungal, infection is becoming 
a serious probl,em. Furthermore, acute invasive 
fungal, infection is associated with a much higher 
mortal,ity. Earl,y diagnosis with prompt antifungal, 
therapy, or even with surgical, intervention, might 
be warranted to save patients' l,ives. 
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Background: Daptomycin is a novel, l,ipopep- 
tide recentl,y approved for treatment of compl,i- 
cated skin and skin structure infections (SSTIs) 
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caused by susceptible Gram-positive bacteria, in- 
cluding methici[[in-resistant S aphylococcus aureus 
(MRSA). Clinical data in pediatric patients is lim- 
ited. 
Methods: A retrospective chart review of pedi- 
atric patients (<18y) who received >2 doses of 
daptomycin between 8/2003 and 11/2006 was per- 
formed. 
Results: Eleven infections [9 Gram-positive bac- 
teremias (GPB) and 2 SSTIs] in 10 patients (7 male, 
3 female) were treated with daptomycin (eight 
received 6 mg/kg/day and three - 4 mg/kg/day). 
Seven patients had hematological malignancies 
(5 ALL, 1 AML, 1 CML) and a[[ were a[[ogeneic 
transplant recipients. Two patients had solid tu- 
mors (neurob[astoma-1 and lung cancer-I). Me- 
dian age was 11 years (range, 2-18). Eight in- 
fections occurred during neutropenia and four 
during corticosteroid therapy. Of the nine bac- 
teremias, a[[ were catheter related (6 CVC, 3 im- 
planted port). Organisms isolated were coagu[ase- 
negative Staphylococcus (CONS): 5; Enterococcus 
J=aecalis: 2, and 2 po[ymicrobia[ infection - CoNS + 
E. mundii, CoNS + Lactobaci[[us. Two infections 
were SSTIs including leg abscess: 1, ce[[u[itis: 1. 
Eleven infections had failed standard antimicrobia[ 
therapy (vancomycin for >4 days in 8 episodes; 
[inezo[id for >3 days in 2 episodes; and quin- 
upristin-da[fopristin - 21 days in 1 episode) 
and had persistently positive blood cultures 
(8 episodes) and/or fever (7 episodes) prior to initi- 
ation of daptomycin. Although susceptible, 4 CoNS 
had vancomycin MlCs of 2.0 ~8/m[ and 3 had MlCs of 
3.0 ~8/m[. The [inezo[id MIC of one E. J=aecalis rose 
from 1.5 to 4.0 ~8/m[ while on daptomycin therapy. 
Median duration of daptomycin therapy was 10 days 
(range, 4-15). Outcomes included clearance of 
blood cultures and defervescence within 72h in 
7 episodes, 1 - grew E. J=aecalis on daptomycin, 
1 - persistently febrile and resolution of both SSTIs. 
No drug related adverse events were documented. 
Conclusion: Daptomycin appears to be a promising 
antimicrobia[ agent for the treatment of GPI in pe- 
diatric cancer patients and merits further clinical 
evaluation. 
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Background: Patients with acute mye[oid leukemia 
(AML) or mye[odysp[astic syndrome (MDS) under- 
going induction chemotherapy are at high risk for 
invasive funga[ infections (IFIs). In a mu[ticenter, 
randomized study of AML/MDS patients, posacona- 
zo[e (POS) prophylaxis prevented significantly more 
breakthrough IFIs than standard azo[e (flucona- 
zo[e [FLU] or itraconazo[e [ITZ]) prophylaxis. 
Objectives: We evaluated mortality rates and 
causes of death in patients from this study who de- 
veloped a breakthrough IFI during POS or standard 
azo[e prophylaxis. 
Methods: Patients with AML or MDS and chemo- 
therapy-induced neutropenia (~<500 ceils/ram 3) 
were randomly assigned to POS oral suspen- 
sion 200m8 tid or oral standard azo[e prophy- 
laxis (FLU suspension 400m8 qd or ITZ solution 
200 m8 bid) with each chemotherapy cycle for ~<12 
weeks. A[[ patients were closely monitored for IFIs 
by current culture, serological, and radiographic 
methods. Primary endpoint was the incidence of 
proven/probable IFIs durin8 the treatment phase 
(from randomization to 7 days after last dose), 
as determined by a blinded expert pane[ using 
EORTC/MSG criteria. Survival information was col- 
lected at 30 days after last dose of study drug or 
100 days after randomization, whichever occurred 
later. Cause of death was investigator-determined. 
Results: 602 patients were enrolled (304 POS; 298 
standard azo[e [240 FLU, 58 ITZ]). Significantly 
fewer IFIs occurred among POS patients (POS, 
7 [2%] vs standard azo[es, 25 [8%]; P=0.0009). 
Aspergi[[osis was the most common IFI in both 
groups, but significantly fewer cases occurred in 
the POS group (POS, 2 [1%] vs standard azo[es, 
20 [7%]; P=0.0001). Overall mortality was n=49 
(16%) and n=67 (22%) for patients in the POS 
and standard azo[e groups, respectively (P = 0.048). 
Of patients who developed a breakthrough IFI, 
1 of 7 (14%) POS patients and 11 of 25 (44%) 
standard azo[e patients died during the study 
(table). The mortality rates for patients with- 
out proven/probable IFIs were 48/297 (16%) and 
56/273 (21%) for POS and FLU/ITZ, respectively. 
